Ulcerative colitis
Drug research and approvals for ulcerative colitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 273 studies of ulcerative colitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 157 drug trials for it since 2013, FDA has 6 approved and 17 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 273
- Trials authorized in Canada: 157
- FDA orphan approvals: 6
- EU medicines: 5
- Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisNCT07932691 · Phase 1 · Beijing VDJBio Co., LTD. · starts Aug 9, 2024
- Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO StudyNCT07916727 · Not applicable · Austin Health · starts Apr 15, 2026
- Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)NCT07913347 · Phase 1 / Phase 2 · Metagen Therapeutics, Inc. · starts Jul 9, 2026
- A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative ColitisNCT07845487 · Phase 2 · Palisade Bio · starts Aug 28, 2026
- A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With…NCT07846683 · Phase 3 · Hoffmann-La Roche · starts Nov 15, 2026
- Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative ColitisNCT07820046 · Phase 2 / Phase 3 · Tanta University · starts Oct 25, 2026
- Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han DonorsNCT07814456 · Phase 2 · First Affiliated Hospital of Kunming Medical University · starts Feb 3, 2026
- Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseNCT07799428 · Not applicable · Anabio R&D · starts Sep 4, 2026
- Familial Inflammatory Bowel Disease Early RiskNCT07791862 · Not reported · Seattle Children's Hospital · starts Mar 26, 2026
Approved 20
- MesalamineArachidonate 5-lipoxygenase inhibitor
- InfliximabTNF-alpha inhibitor
- VedolizumabIntegrin alpha-4/beta-7 inhibitor
- AdalimumabTNF-alpha inhibitor
- GolimumabTNF-alpha inhibitor
- EtrasimodSphingosine 1-phosphate receptor Edg-1 agonist
- BudesonideGlucocorticoid receptor agonist
- MirikizumabInterleukin-23 inhibitor
- UstekinumabInterleukin-12 inhibitor
- OzanimodSphingosine 1-phosphate receptor Edg-1 modulator
- PrednisoneGlucocorticoid receptor agonist
- BalsalazideArachidonate 5-lipoxygenase inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- Phytonadione
- OlsalazineArachidonate 5-lipoxygenase inhibitor
- SulfasalazineArachidonate 5-lipoxygenase inhibitor
- Betamethasone acetateGlucocorticoid receptor agonist
- Betamethasone phosphoric acidGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- Isopropyl alcohol
Phase 3 12 of 23
- TofacitinibJanus Kinase (JAK) inhibitor
- EtrolizumabIntegrin beta-7 antagonist
- ObefazimodCap binding complex modulator
- OntamalimabMucosal addressin cell adhesion molecule-1 inhibitor
- GuselkumabInterleukin-23 inhibitor
- UpadacitinibTyrosine-protein kinase TYK2 inhibitor
- TetomilastPhosphodiesterase 4 inhibitor
- Andrographolide
- AzathioprineAmidophosphoribosyltransferase inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- FilgotinibTyrosine-protein kinase JAK1 inhibitor
- RisankizumabInterleukin-23 inhibitor
Phase 2 12 of 84
- VisilizumabT-cell surface glycoprotein CD3 epsilon chain inhibitor
- MetronidazoleDNA inhibitor
- VancomycinPeptidoglycan inhibitor
- AbrilumabIntegrin alpha-4/beta-7 inhibitor
- SpesolimabIL36 receptor antagonist
- Interferon beta-1aInterferon alpha/beta receptor agonist
- AndecaliximabMatrix metalloproteinase 9 inhibitor
- EldelumabC-X-C motif chemokine 10 inhibitor
- IzencitinibJanus Kinase (JAK) inhibitor
- Phosphatidylcholine
- TOP-1288
- Vimekofusp
Phase 1 or earlier 12 of 35
- ErgocalciferolVitamin D receptor agonist
- OmeprazolePotassium-transporting ATPase inhibitor
- IndomethacinCyclooxygenase inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- Muromonab-CD3T cell surface glycoprotein CD3 inhibitor
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Berberine
- DextromethorphanSigma opioid receptor agonist
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- CaffeineAdenosine receptor antagonist
- Aminolevulinic acidDNA inhibitor
- SolcitinibTyrosine-protein kinase JAK1 inhibitor
How its trials ended
1,195 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 337 whose ending is known, 42% met their primary endpoint, 7% missed it and 51% stopped early.
- Completed, result not reported40534%
- Ongoing29925%
- Status unknown15413%
- Met its primary endpoint14112%
- Stopped: other or unclear716%
- Stopped: enrollment or feasibility434%
- Stopped: sponsor or business decision272%
- Stopped: lack of efficacy262%
- Missed its primary endpoint232%
- Stopped: safety3<1%
- Stopped: funding3<1%
| Oct 1, 2026 | A randomized trial of RIPK2 inhibitor OD-001 in combination with vedolizumab for moderately to severely active ulcerative colitisOD-001 (OD-07656) / Vedolizumab | Odyssey Therapeutics | Pending |
| Sep 17, 2026 | A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy, safety, pharmacokinetics, and…PALI-2108 | Palisade Bio, Inc. | Pending |
| Aug 25, 2026 | A phase 2 platform basket study evaluating advanced therapies in subjects with moderately to severely active Crohn's disease or ulcerative colitisRisankizumab (ABBV-066) / Trosunilimab / ABBV-701 | AbbVie | Ongoing |
| Aug 12, 2026 | A phase III, multicenter, double-blind, placebo-controlled study to assess the efficacy and safety of induction therapy with RO7790121 in patients with…RO7790121 (TL1A (RVT-3101)) | Roche | Pending |
| May 20, 2026 | A phase 3 randomized, double-blind, and active-controlled, multicenter study to evaluate the efficacy and safety of JNJ-78934804 in participants with…JNJ-78934804 (guselkumab-golimumab) / Guselkumab | Johnson & Johnson | Ongoing |
| Apr 24, 2026 | A phase 2a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-8690 in adult participants with moderately to severely…MK-8690 | Merck & Co. (MSD) | Ongoing |
| Apr 2, 2026 | Master protocol title: a master protocol for phase 2, randomized, controlled studies of multiple interventions for the treatment of adults with moderately to…Mirikizumab (LY3074828) / LY4395089 | Eli Lilly | Ongoing |
| Mar 25, 2026 | A randomized, multicenter, double-blind, placebo-controlled development program to evaluate the efficacy and safety of LY4268989 (MORF-057) for the treatment…LY4268989 (MORF-057) | Eli Lilly | Ongoing |
| Feb 20, 2026 | A phase 2, multicenter, randomized, double-blind, active-controlled study of LY4268989 (MORF-057) co-administered with mirikizumab in adults with moderately to…LY4268989 (MORF-057) / Mirikizumab (LY3074828) | Eli Lilly | Ongoing |
| Feb 4, 2026 | A multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility…Fecal microbiota for transplantation (FMT) | The Governors of The University of Alberta | Pending |
| Aug 28, 2026 | StelaraTreatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitis | Janssen Biotech, Inc. | Approved |
| Oct 7, 2025 | SimponiTreatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis | Janssen Biotech, Inc. | Approved |
| Feb 24, 2021 | HumiraTreatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The… | AbbVie, Inc. | Approved |
| Jun 26, 2020 | LialdaLialda (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at… | Takeda Development Center Americas, Inc. | Approved |
| Sep 23, 2011 | RemicadeFor reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with… | Janssen Biotech, Inc. | Approved |
| Dec 20, 2006 | ColazalTreatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal… | Salix Pharmaceuticals, Inc. | Approved |
| Aug 9, 2021 | Mixture of delta 9-tetrahydrocannabinol glycosidesTreatment of pediatric ulcerative colitis between the ages of 0-18 years | Vitality Biopharma, Inc. | Designated |
| Mar 30, 2020 | Magnesium lysinate bis Resolvin E1Treatment of pediatric ulcerative colitis | Thetis Pharmaceuticals | Designated |
| Dec 30, 2019 | UpadacitinibTreatment of pediatric ulcerative colitis | AbbVie | Designated |
| Jan 17, 2018 | ApremilastTreatment of pediatric patients with ulcerative colitis | Amgen Inc. | Designated |
| Nov 16, 2017 | Cholera toxin B subunitTreatment of ulcerative colitis in pediatric patients | Aliment Wellness LLC | Designated |
| Aug 31, 2017 | 5-(4-carboxymethyl-phenylazo)-2-hydroxybenzoic acid…Treatment of pediatric ulcerative colitis (UC) | 9 Meters Biopharma, Inc. | Designated |
| Jun 27, 2017 | Hydrocortisone acetateTreatment of pediatric ulcerative colitis | Cristcot HCA, LLC | Designated |
| Jun 15, 2017 | Humanized immunoglobulin G4-variant monoclonal antibody…Treatment of ulcerative colitis in pediatric patients | Eli Lilly & Company | Designated |
| Dec 29, 2015 | OzanimodTreatment of pediatric (0 through 16 years of age) ulcerative colitis | Celgene Corporation | Designated |
| Feb 16, 2024 | VelsipityEtrasimod | Pfizer Europe MA EEIG | EMA ↗ |
| May 26, 2023 | OmvohMirikizumab | Eli Lilly Nederland B.V. | EMA ↗ |
| May 20, 2020 | ZeposiaOzanimod | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| May 18, 2018 | ZesslyInfliximab · biosimilar | Sandoz GmbH | EMA ↗ |
| May 22, 2014 | EntyvioVedolizumab | Takeda Pharma A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA